Diet and Weight Reducing Centers NAICS 812191

Nov 4, 2025 - Obesity Rate Falls as Injectables Use Surges

• According to Gallup’s National Health and Well-Being Index, the US adult obesity rate has declined from 39.9% in 2022 to 37.0% in 2025, representing 7.6 million fewer obese adults in a shifting weight loss landscape. This shift coincides with a surge in GLP-1 injectable use for weight loss, rising from 5.8% to 12.4% since early 2024. For the weight loss program industry, this trend signals a competitive shift as consumers increasingly turn to pharmaceutical solutions like semaglutide (Ozempic, Wegovy). Traditional programs can adapt by integrating medical weight management options or emphasizing lifestyle support. Usage is highest among adults aged 50–64 (17.0%) and 40–49 (16.2%), who also saw the largest drops in obesity rates. With 89% of Americans now aware of GLP-1s and 13 states covering them under Medicaid, accessibility is expanding. However, diabetes diagnoses continue to rise, underscoring the need for holistic approaches beyond medication.
• Softening consumer confidence and sentiment in October 2025 may dampen discretionary spending, posing challenges for the diet and weight reducing centers industry. The Conference Board’s Consumer Confidence Index edged down to 94.6 from 95.6, as improved current conditions (Present Situation Index up to 129.3) were offset by weaker short-term expectations (Expectations Index down to 71.5). Inflation expectations rose to 5.9%, and over half of consumers anticipated higher interest rates. Holiday spending is projected to fall, with promotions driving purchasing decisions. Meanwhile, the University of Michigan’s Index of Consumer Sentiment dropped 2.7% month-over-month to 53.6, a 24.0% year-over-year decline. The Current Economic Conditions Index fell to 58.6, and the Expectations Index to 50.3, down 32.1% annually. Year-ahead inflation expectations eased to 4.6%, while long-run expectations rose to 3.9%, with increased uncertainty across both horizons.

• WeightWatchers exited Chapter 11 bankruptcy in June 2025, reducing its debt load by $1.15 billion, the company announced. WeightWatchers has struggled in recent years to adapt its business model to the fast-changing weight loss industry, which has been upended by weight-loss drugs like Ozempic. While the company has added a clinical component incorporating weight-loss drugs, the growth has not been fast enough to offset a decline in subscriptions to its core programs. CEO Tara Comote said the company expects to accelerate its transformation following the bankruptcy. It is adding a new program aimed at supporting women through perimenopause, menopause, and post menopause with clinical care, nutritional strategies, and coaching. Per Comote, “Our integrated model, spanning clinical care, behavioral support, and community, puts us in a powerful position to reinforce our leadership in long-term weight health.”
• According to a recently released report by the National Center for Health Statistics in Deseret News, the average weight for US adults and teens has tipped the scale into the obesity range. The study analyzed the body composition of thousands of Americans between August 2021 and August 2023. The average adult male 20 and older was slightly under 5-foot-9 and weighed 199 pounds, with a resulting body mass index of 29.4, which is considered overweight. For women, the average adult female was 5-foot-31/2 and weighed 171.8 pounds, which provided a BMI of 30, considered obese. A BMI of between 18.5 and 24.9 is considered in the normal range for adults, 25 to 29.9 is overweight, and over 30 is obese. The report showed that the share of children who have obesity increases with age, with children tipping into the overweight category as they reach adulthood.